Boulder biotech company ViroCyt, a leader in rapid virus quantification, announced Tuesday that Greg Krueger has been appointed vice president of global sales.
“(Greg) brings a wealth of experience and contacts within our targeted markets,” said Robert Kline, president and CEO of ViroCyt, 2100 Central Ave. “As our business continues to scale, Greg will be adding to and directing our domestic and international channel resources.”
Krueger has previously held sales, marketing and business development positions at Sartorius Stedim Biotech, Becton Dickinson, Accuri Cytometers, GE Healthcare, Pharmacia and Amersham.
“The opportunity to work with such an experienced and focused group is truly exciting,” Krueger said. “I look forward to continuing to meet the impressive global demand for ViroCyt’s innovative technologies, which are being used to save time and money bringing life-saving vaccines and therapies to the marketplace.”
ViroCyt, previously part of another Boulder life science company, InDevR, announced in June that it had raised $4 million to expand its global operations.
